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Abstract
Background: The well-being of breast cancer patients and reporting of adverse events require close monitoring. Mobile apps
allow continuous recording of disease- and medication-related symptoms in patients undergoing chemotherapy.
Objective: The aim of the study was to evaluate the effects of a mobile app on patient-reported daily functional activity in a
supervised and unsupervised setting.
Methods: We conducted a randomized controlled study of 139 breast cancer patients undergoing chemotherapy. Patient status
was self-measured using Eastern Cooperative Oncology Group scoring and Common Terminology Criteria for Adverse Events.
Participants were randomly assigned to a control group, an unsupervised group that used a mobile app to record data, or a supervised
group that used the app and reviewed data with a physician. Primary outcome variables were change in daily functional activity
and symptoms over three outpatient visits.
Results: Functional activity scores declined in all groups from the first to second visit. However, from the second to third visit,
only the supervised group improved, whereas the others continued to decline. Overall, the supervised group showed no significant
difference from the first (median 90.85, IQR 30.67) to third visit (median 84.76, IQR 18.29, P=.72). Both app-using groups
reported more distinct adverse events in the app than in the questionnaire (supervised: n=1033 vs n=656; unsupervised: n=852
vs n=823), although the unsupervised group reported more symptoms overall (n=4808) in the app than the supervised group
(n=4463).
Conclusions: The mobile app was associated with stabilized daily functional activity when used under collaborative review.
App-using participants could more frequently report adverse events, and those under supervision made fewer and more precise
entries than unsupervised participants. Our findings suggest that patient well-being and awareness of chemotherapy adverse
effects can be improved by using a mobile app in collaboration with the treating physician.
ClinicalTrial: ClinicalTrials.gov NCT02004496; https://clinicaltrials.gov/ct2/show/NCT02004496 (Archived by WebCite at
http://www.webcitation.org/6k68FZHo2)
(J Med Internet Res 2016;18(9):e238)   doi:10.2196/jmir.6414
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Introduction
Telemedicine services have historically provided education,
hardware, and software to patients and have been shown to
improve functional status. If symptoms worsen, automatic
algorithms to alert the nurse or physician have been
demonstrated to be more effective than patient self-reporting
alone [1]. The advent of mobile apps and the ease with which
these are developed and used enables the stakeholders to
collaborate in an increasingly dynamic and efficient manner.
Until now, mobile apps that allow continuous recording of
disease- and medication-related symptoms have only
occasionally been implemented in the management of patients
undergoing chemotherapy [2]. However, symptom self-reporting
on paper can only be explored with cumbersome efforts. In
particular, therapeutic regimens in cancer patients require
intensive monitoring procedures [3] because outpatient
chemotherapy may frequently be accompanied by serious and
potentially life-threatening adverse effects [4,5]. Well-informed
patients spend significant efforts in documentation and
management of symptoms as well as reviewing information
related to both during the course of their disease and therapeutic
interventions [6]. Consequently, involved physicians
increasingly need to focus on collection and interpretation of a
variety of information presented during the patient’s visit at
first and after appropriate measures, if indicated.
Mobile apps have raised high expectations in various settings
of daily life; their potential is now increasingly being examined
in the health care sector. Supporting self-care with information
on the disease or symptoms during routine cancer care can be
enhanced by remote devices and patient collaboration through
online patient groups and other forums [7]. In addition, recent
studies have shown that the reporting of symptoms via email
reminder and improved previsit preparation of physicians via
printouts of symptoms may increase patients’ well-being [8].
Moreover, ancillary disease-related counseling with or without
use of electronic devices successfully improved patient
satisfaction through better understanding of specific symptoms,
which in turn decreases patient anxiety [9]. Thus, available data
indicate that mobile apps may well improve patient status if
applied in a supervised setting in which the physician is
empowered by additional information or services. However,
the question remains whether self-quantifying apps, such as
step counters, will provide added value simply by empowering
the patient in an unsupervised setting.
Our objective was to explore the impact of a mobile and
Web-based app in both an unsupervised setting and a setting
supervised by the treating physician. We conducted a
prospective randomized trial and invited early breast cancer
patients to continuously record their symptoms according to the
Common Terminology Criteria for Adverse Events (CTCAE)
v4.0 via a novel electronic study device (mobile or Web app)
and to also indicate their Eastern Cooperative Oncology Group
(ECOG) Performance Status. Information for supportive care
was also displayed by the app depending on the severity of
symptoms upon data entry. The cumulative recorded data were
made available to the patient in chart form (similar to a stock
chart) at any time during the study. In the unsupervised setting,
patients were instructed to use the app at any time except during
study visits. In the supervised setting, the treating physician
accessed the recorded data and patient-derived charts using the
Web app during the study visit.
Methods
Study Design
We conducted a single center, three-arm, randomized,
controlled, single-blinded interventional study. The protocol
was approved by the Swiss Institutional Review Board
(KEK-EK-ZH:2013-0200) and registered on ClinicalTrials.gov
(NCT02004496). Patients with early breast cancer, aged 18
years and older, and initiating adjuvant or neoadjuvant
chemotherapy at the Breast-Center Zürich were eligible to
participate upon written informed consent. In addition,
participants had to speak German and own a mobile phone.
Study Groups
Eligible participants were recruited consecutively and without
preselection during planning of chemotherapy. Participants
received an envelope randomly assigning them to one of three
study groups. The allocation sequence was concealed by the
use of sealed, sequentially numbered, opaque envelopes. Group
A (control) was the control group and received regular physician
support. Group B (app) patients were instructed to use the
mobile app without physician review. Group C (app and
physician) patients used the mobile app and reviewed the
reported data with the treating physician at scheduled visits.
Participants in each group underwent three regular medical
oncology visits scheduled on days 1, 21, and 42 during their
chemotherapeutic intervention and independently of the study.
The physician was single-blinded with regard to groups A and
B. At the end of each visit, patients in all groups completed a
questionnaire on paper. The observation period comprised 6
weeks and was initiated on the day of the first infusion therapy.
Questionnaire
The questionnaire recorded performance status and daily
functional activities according to the ECOG scale in an attempt
to quantify daily levels of activity among breast cancer patients.
The first five categories were presented as a visual analog scale;
the sixth category, death, was omitted from the questionnaire.
The ECOG activity score measure is routinely used to evaluate
whether patients are eligible for chemotherapy, whether dose
adjustments are required, and as an indicator for the need of
palliative care. Additional questions were posed to further
characterize the quality of care received by patients and the
relationship between the patient and physician (Table 1). In
addition, 30 preselected adverse events were listed with
selectable severity, onset, and duration. The most frequent
symptoms were selected according to clinical preview and
experience; furthermore, patients could add additional symptoms
as free text. Any medical measures undertaken could also be
reported as free text. The questionnaire was issued to all groups
at each of the three scheduled visits during the 6 weeks of study.
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Table 1. Questions regarding the relationship between patient and physician for the three visits for each patient group.
Group and visit number, median (IQR)aQuestions
App and physicianAppControl
321321321
4c (12)4b,c (18)3 (29)4c (10)2c (8)10 (51)17b (64)6b (77)13 (69)Concentration problems
during visit
96 (12)94 (14)94 (21)95 (14)95 (20)94 (20)94 (20)94 (35)94 (15)Well-informed about thera-
py
96 (30)96 (14)96 (18)95 (15)93 (24)92 (24)94 (19)94 (31)92 (25)Well-informed about disease
4 (6)1c (8)2 (10)4 (13)2b,c (5)4 (10)6 (17)6b (73)4 (40)Less likely to disfavor with
care
100 (15)100 (14)100 (13)98 (13)96 (18)96 (21)94 (15)94 (14)96 (23)Awareness regarding ad-
verse events
100 (7)99 (11)100 (12)98 (11)96 (10)99 (12)95 (17)96 (14)96 (10)Satisfaction with medical
care
100 (8)100 (7)100 (11)100 (8)95 (11)98 (13)99 (13)99 (13)96 (14)Trust in data security
99 (8)100 (8)100 (12)99 (11)96 (11)96 (17)94 (19)96 (17)98 (18)Feeling of being taken seri-
ously
a Value of 0 indicates complete disagreement, whereas 100 represents complete agreement with the statement in the question.
b,c Annotations mark significant differences between the three groups. In this case three combinations of group pairs are possible. Two groups differ
significantly in the answer to the question if they have different superscript characters.
Mobile App
We developed a novel open-source mobile and Web app to
record daily functional activity and adverse events. This mobile
app was made available in the Apple and Google Android stores
free of charge. Patients could report daily functional activity or
symptoms with indication of severity in the electronic app device
similar to the paper questionnaire. The visual analog scale from
the questionnaire was substituted with a horizontal slider.
Similar to the questionnaire, the label of symptom severity and
category according to CTCAE was displayed below the slider.
During the visits, nurses reminded the participants according
to their randomization to use the app, but no other reminders
were issued. Patients could edit a quick list of their preselected
symptoms or select any of the 48 symptoms made available
from the CTCAE listing. Only for group C was the treating
physician enabled access to review and discuss the electronically
reported symptoms during scheduled visits. Although the mobile
app was publically available for download and use, only study
patients who scanned an issued QR code containing a shared
password could upload and store data securely. The development
was frozen during the trial.
The variables of daily functional activity and severity of
symptoms from the questionnaire and the mobile app were
transformed to the same interval (0-100), if applicable. Missing
data or withdrawn subjects were not excluded from the analysis
to prevent selection bias for successfully compliant patients.
Sample Size
We calculated the sample size for the three groups based on a
10% difference in daily functional activity. The significance
level, after Bonferroni correction for the comparison of the three
groups, was .016 (P=.05/3). A mean of 80% (SD 13%) was
estimated by reviewing medical records of randomly selected
patients at the Breast-Center Zürich. To detect differences with
a power of 91%, a sample size of 50 patients per group was
calculated. Given this sample size, a power of 80%, and a mean
frequency of 4.4 (SD 3.3) adverse events, we expected to detect
a difference in mean frequency of 2.2 adverse events per group.
To minimize bias in the groups, only patients under the care of
a single physician, who also participated as the study physician,
were recruited.
Statistical Analysis
All statistical tests were calculated using SPSS version 22.0
(IBM Corp, Armonk, NY, USA). Two-sided P values of less
than .05 were considered to indicate statistical significance. For
cases of more than two independent samples, Bonferroni
correction was applied. Descriptive statistics, such as median
and interquartile range, were computed. The Kruskal-Wallis
test was used to identify differences in outcome variables among
the three groups at all time intervals. The Mann-Whitney test
further investigated differences between groups B and C. The
paired Wilcoxon test analyzed the differences between time
intervals within one group. Scatterplots and Spearman
correlation (ρ) were used to validate the reported data from the
app against the questionnaire.
Results
Baseline Characteristics
Between December 2013 and July 2015, 139 patients were
enrolled, 12 of whom did not complete the study for various
reasons (Figure 1). Dislike of the constant confrontation with
the disease was the reason for withdrawal for five of 12 patients
who withdrew. The remaining 127 patients completed all three
study visits. Baseline characteristics were equally distributed
between the groups (Table 2). The most frequent chemotherapy
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regimen in all groups was epirubicin/cyclophosphamide (n=32),
followed by paclitaxel/trastuzumab (control: n=8; app: n=4; app
and physician: n=7), and paclitaxel/carboplatin (control: n=4;
app: n=8; app and physician: n=7). In total, six different
chemotherapy regimens were reported using seven distinct
chemotherapeutic agents. The median observation interval
between visit 1 and visit 2 (IQR 6), and also between visit 2
and visit 3 (IQR 8), was 21 days.
Figure 1. CONSORT diagram demonstrating the flow of patients.
Table 2. Summary of baseline characteristics of participants.
App and physician
(n=49)
App (n=46)Control (n=44)All patients (N=139)Characteristics
53 (12)50 (10)56 (15)53 (13)Age (years), mean (SD)
49 (100)46 (100)44 (100)139 (100)Sex (female), n (%)
Chemotherapy, n (%)
31 (63)30 (65)25 (57)86 (61.9)Adjuvant
16 (33)16 (35)18 (41)50 (36)Neoadjuvant
Surgery, n (%)
17 (35)16 (35)17 (39)50 (36)Biopsy (sentinel)
22 (45)27 (59)23 (52)72 (51.8)Breast conserving
8 (16)3 (7)3 (7)14 (10.1)Breast ablation
Interval (days), median (IQR; range)
21 (2; 7-42)20 (6; 7-27)21 (6; 6-43)21 (6; 6-43)Visits 1-2
20 (7; 6-28)21 (7; 7-28)21 (9; 7-42)21 (8; 6-42)Visits 2-3
39 (7; 13-56)41 (9; 26-49)42 (2; 14-84)42 (7; 13-84)Visits 1-3
Daily Functional Activity
We collected 381 questionnaires from patients who completed
the study. Current daily functional activity was indicated as the
ECOG score at the time of the study visit, whereas the worst
daily functional activity was defined as the worst rating before
visits 1 to 3, respectively.
As shown in Figure 2, both median current and worst daily
functional activity declined in all patients during chemotherapy
from the first to the second visit. From the second to the third
visit, only patients in group C (app and physician) reported
improvement in their functional activity, whereas scores in
groups A (control) and B (app) continued to decline. From the
first to the third visit, group A (current: median 90.24, IQR
19.63 vs median 75.61, IQR 21.95, P=.006; worst: median
84.15, IQR 23.93 vs median 71.95, IQR 32.32, P=.02) and group
B (current: median 90.24, IQR 21.47 vs median 74.39, IQR
21.95, P=.02; worst: median 84.76, IQR 36.20 vs median 62.80,
IQR 26.83, P<.001) showed a significant decline in functional
activity in contrast to group C (current: median 90.85, IQR
30.67 vs median 84.76, IQR 18.29, P=.72; worst: median 84.15,
IQR 39.88 vs median 65.24, IQR 32.32, P=.13). However,
within the three groups differences in the reported functional
activity at the three visits did not reach statistical significance,
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irrespective of whether current or worst daily functional activity
was analyzed. Post hoc, the sample size for the actual standard
deviation of 17% and a power of 91% should have required at
least 83 patients per group in order to demonstrate a significant
difference between the groups.
Overall, for groups B and C, results from the questionnaire were
partially aligned with the data derived from app use. Patients
started electronic recording of daily functional activity and
symptoms in the app after the first visit, which also was the first
day of treatment. The last data entry before each visit
corresponded to the current daily functional activity indicated
in the questionnaire at the visit. Similar to the results obtained
from the questionnaire, the current daily functional activity (last
value) declined significantly from the second (median 79.50,
IQR 89.00) to the third visit (median 73.00, IQR 85.00) in group
B (P=.007), but not in group C (median 75.00, IQR 90.00 vs
median 70.00, IQR 84.00, P=.90). In addition, the best functional
activity score of patients in group B (median 85.50, IQR 94.00
vs median 78.50, IQR 91.00, P=.008), but again not in group
C (median 80.00, IQR 98.00 vs median 72.00, IQR 91.00,
P=.34) dropped significantly in the first interval compared with
the second interval.
In contrast, the median of the worst daily functional activity
recorded in the app showed no significant difference in groups
B and C between the first and second interval. The median over
the total interval in the app-derived scores was not significantly
lower for group B than for group C (median 45.50, IQR 49.00
vs median 45.00, IQR 70.00, P=.26) compared to almost
identical results derived from the questionnaire for groups B
and C (median 62.80, IQR 26.83 vs median 65.24, IQR 32.32,
P=.07), respectively.
Figure 2. Visual analog scale for current and worst daily functional activity in the questionnaire.
Patient Communication
We further analyzed different aspects of the patient-physician
relationship in each group (Table 1). In general, all patients felt
very well informed about their disease and treatment, and were
highly satisfied with their medical care. During the second visit,
only group B reported significantly fewer concentration issues
than group A (P=.006). In addition, group A was significantly
less likely to express dissatisfaction with quality of care at the
second visit than group C (P=.03). Most importantly, at the last
visit, patients in groups B and C reported significantly fewer
issues with concentration than patients in group A (P=.002).
Patient Empowerment
As the study progressed, patients in all groups were significantly
more likely to change their responses to the question about
whether they used the Internet to obtain further information
about their disease (Figure 3). At the third visit, significantly
more patients in groups B (64.29% P=.04) and C (70.73%,
P=.007) confirmed use of the Internet for this purpose compared
with group A (41.46%).
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Figure 3. Participants who used the Internet to obtain disease-specific information.
Symptom Reporting
The most frequently reported symptoms in the app were fatigue,
hair loss, headache, and hypertension; from the questionnaire,
fatigue, dry skin, headache, and sleep disorder were most
prevalent. Regarding the number of distinct symptoms reported
in the questionnaire and app, only group C showed a significant
correlation in the interval from the first to the second visit
(ρ=.381, P=.009) and from the second to the third visit (ρ=.362,
P=.02), respectively.
Both groups reported more distinct symptoms in the app than
in the questionnaire, a trend that was less prominent in group
B than in group C. Therefore, the difference in numbers of
distinct symptoms reported in the app versus the questionnaire
was greater in group C (difference 377=1033−656) than in group
B (difference 29=852−823). However, group B reported more
symptoms in total (n=4808) in the app than group C (n=4463).
Furthermore, group C reported significantly more distinct
symptoms (median 13.00, IQR 12.00, P=.04) in the app for the
total intervention interval, and more distinct mild symptoms
(median 8.00, IQR 11.00, P=.02) in the interval from the first
to the second visit compared with group B (distinct total: median
9.00, IQR 13.00; distinct mild: median 5.00, IQR 11.00). As
for group A, the amount of distinct symptoms reported in the
questionnaire was comparable to group C, whereas group B
reported approximately 25% more symptoms.
Discussion
Principal Results
Few data exist that have addressed modalities and effects of
electronic symptom reporting in patients undergoing
chemotherapy. We demonstrate that a mobile app merits the
potential to stabilize the daily functional activity of early breast
cancer patients. Supervision and review of patient-reported
symptoms in collaboration with their physician encouraged a
timely and sincere discussion of symptoms reported in the app.
Moreover, despite a rather short intervention period, supervised
patients (group C) experienced a significant benefit with respect
to daily functional activity in contrast to the unsupervised
patients (group B and controls). These findings are in accordance
with data gained from advanced cancer patients with longer
follow-up managed by email prompts [8].
Patient-physician collaboration might have influenced the
patients in three ways. First, the stabilization of daily functional
activity seemed partially linked to a change in behavior, reflected
by a more precise recording of symptoms in supervised patients,
whereas fewer data entries were recorded than in unsupervised
patients. Potentially augmenting existing mechanisms for
symptom management along with routine oncology care,
supervised app users also seemed to attain the ability to better
differentiate and communicate their treatment-related symptoms,
which consequentially facilitates appropriate management by
the physician.
Furthermore, supervised patients were more likely than
unsupervised patients and controls to communicate their
dissatisfaction. It seems plausible that an increase in
self-confidence may also positively affect daily functional
activity. Strengthened self-confidence is likely reflected in
decreasing incidence of concentration issues reported during
the visits and an increasing use of the Internet to obtain further
information about disease and related treatment in both groups
using the mobile app. Previous studies also indicate that
physicians, as well as the majority of patients, believe that
mobile apps facilitate communication [10] and increase the
frequency of discussion [11] during consultations.
In addition, patients receiving chemotherapy frequently report
cognitive impairments [8]. In our study, both the supervised
and unsupervised groups recorded improvements in worst daily
functional activity in the app before the visit, although this
became less evident from the questionnaires during the visit.
The diary character of our mobile app is helpful for recalling
disease-related information. This feature may have positive and
negative consequences. Patients in group C reported impaired
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and probably more accurate scores for worst daily functional
activity compared to the controls.
Six patients in group C withdrew from the study because of
software reasons. One patient had functional problems with the
recording of symptoms in the app. Five patients withdrew their
participation from the study to avoid the constant confrontation
with their disease. Of note, these patients in group C had the
worst reported daily functional activity between the first and
second visit. In general, group C was more likely to
communicate their dissatisfaction with quality of care than group
B and the controls. Maybe also patients in group B would have
withdrawn from the study if their communication skills had
been comparably strengthened. Furthermore, the daily recording
of symptoms plus the supervision of symptoms during the visit
in group C might be an additional burden. For some patients,
this continuous workup of their symptoms might be too intense.
Limitations
There are several limitations of this study. The three groups did
not differ significantly from one another with respect to daily
functional activity scores because the sample size turned out to
be inadequate for the effect size observed. However, the three
groups would have reported significantly different daily
functional activity scores in favor of group C if withdrawn
patients had not been included in the analysis. Similar findings
have been reported for supervised cohorts of patients in previous
studies [8,11].
Efforts were made to blind the physician to group A and B
randomization. However, the physician may have inferred from
the patients’ behavior whether they belonged to the control or
the unsupervised app group. Unblinding of the physician and
the patient to the intervention may have affected the patients’
responses to the questions, especially because the patient
completed the questionnaire following consultation with the
physician. However, patients reported congruent answers in the
mobile app outside the clinic.
Different chemotherapeutic regimens may cause different
adverse events. We cannot exclude that effects observed on
daily functional activity were thereby affected. We maintain,
however, that the randomized design of the study and a balanced
distribution of treatment regimens renders a systematic bias
unlikely.
It should be noted that no alert signals about technical issues
and data safety were raised during the entire course of the study.
Conclusion
Mobile apps increasingly contribute to patient education, disease
self-management, and remote monitoring of patients [12]. We
demonstrate that only a collaborative review of timely reported
and naïve, although patient-derived, symptoms has beneficial
effects on daily living activity in early breast cancer patients.
The use of mobile apps under supervision may enable patients
to report adverse events more precisely in the context of
increasingly complex cancer therapies and limited resources.
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